https://www.selleckchem.com/products/l-name-hcl.html To evaluate the inhibitory interaction of thymohydroquinone against blood-brain barrier (BBB)-associated neuropsychiatric and neurodegenerative disorders. An elaborated study was designed to evaluate the interaction of thymohydroquinone with BBB-disrupting proteins and to highlight its pharmacokinetic and safety attributes. Thymohydroquinone demonstrated stable interaction with BBB-disrupting protein active site with Ki (inhibition constant) ranges of (2.71mM-736.15μM), binding energy (-4.3 to5.6Kcal/mol), ligand efficiency (-0.36 to0.42Kcal/mol) and root mean square deviation value of (0.80-2.59Å). Further pharmacokinetic analysis revealed that thymohydroquinone is BBB and central nervous system (CNS) permeant with high acute toxicity and could be a candidate drug for the treatment of these neurological conditions. Further pharmacokinetic analysis revealed that thymohydroquinone is BBB and central nervous system (CNS) permeant with high acute toxicity and could be a candidate drug for the treatment of these neurological conditions. The value of anti-epileptic therapy in the prophylaxis of post-traumatic seizures. All patients received a standard anti-epileptic drug (AED) and were divided into two groups Group A -with early AED and Group B -with late AED. Patients (871/1062) met the inclusion criteria. Multivariate analysis demonstrated that computer tomography findings, headache and prior history of brain head injury were independent risk factors of seizures. Only late post-traumatic seizures (LPTS) was significantly associated with AED (p < 0.05). Early treatment with AED seems to not affect the incidence of lPTS. In addition, an AED with a mean time of initiation of 7.5days from the moderate traumatic brain injury occurrence could reduce the lPTS incidence. Early treatment with AED seems to not affect the incidence of lPTS. In addition, an AED with a mean time of initiation of 7.5 days from the moderate traumat